JP2004532886A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532886A5
JP2004532886A5 JP2003501845A JP2003501845A JP2004532886A5 JP 2004532886 A5 JP2004532886 A5 JP 2004532886A5 JP 2003501845 A JP2003501845 A JP 2003501845A JP 2003501845 A JP2003501845 A JP 2003501845A JP 2004532886 A5 JP2004532886 A5 JP 2004532886A5
Authority
JP
Japan
Prior art keywords
aminocarbonyl
ethoxycarbonyl
piperazin
carbonyl
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003501845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532886A (ja
JP4409936B2 (ja
Filing date
Publication date
Priority claimed from US10/163,742 external-priority patent/US6861424B2/en
Application filed filed Critical
Publication of JP2004532886A publication Critical patent/JP2004532886A/ja
Publication of JP2004532886A5 publication Critical patent/JP2004532886A5/ja
Application granted granted Critical
Publication of JP4409936B2 publication Critical patent/JP4409936B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003501845A 2001-06-06 2002-06-06 血小板アデノシン二リン酸受容体アンタゴニスト Expired - Fee Related JP4409936B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29649801P 2001-06-06 2001-06-06
US10/163,742 US6861424B2 (en) 2001-06-06 2002-06-05 Platelet adenosine diphosphate receptor antagonists
PCT/US2002/017821 WO2002098856A2 (en) 2001-06-06 2002-06-06 Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists

Publications (3)

Publication Number Publication Date
JP2004532886A JP2004532886A (ja) 2004-10-28
JP2004532886A5 true JP2004532886A5 (https=) 2009-08-20
JP4409936B2 JP4409936B2 (ja) 2010-02-03

Family

ID=26859907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003501845A Expired - Fee Related JP4409936B2 (ja) 2001-06-06 2002-06-06 血小板アデノシン二リン酸受容体アンタゴニスト

Country Status (5)

Country Link
US (4) US6861424B2 (https=)
EP (1) EP1412349A2 (https=)
JP (1) JP4409936B2 (https=)
AU (1) AU2002316191A1 (https=)
WO (1) WO2002098856A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
DE60333866D1 (de) * 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
WO2005009971A1 (ja) * 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
EP1812429A4 (en) * 2004-09-29 2010-07-21 Portola Pharm Inc SUBSTITUTED 2H-1,3-BENZOXAZIN-4 (3H) -ONE
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
US7826982B2 (en) * 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
US20100210635A1 (en) * 2006-03-29 2010-08-19 Takeda Pharmaceutical Company Limited Renin inhibitors
US20070254861A1 (en) * 2006-04-28 2007-11-01 Astellas Pharma Inc. Methods for the prevention and/or treatment of peripheral arterial disease
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) * 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
EP1967513A1 (en) * 2007-03-08 2008-09-10 Rheinische Friedrich-Wilhelms-Universität Bonn Novel P2Y12 receptor antagonists
MX2009011089A (es) * 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
AU2008266515B2 (en) 2007-06-18 2014-05-01 Sanofi Pyrrole derivatives as P2Y12 antagonists
EP2225253B1 (en) * 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
EP2238128B1 (en) * 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) * 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20100160323A1 (en) * 2008-12-23 2010-06-24 Alexander Bischoff NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
US8729095B2 (en) 2009-08-28 2014-05-20 Daiichi Sankyo Company, Limited 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
US8889688B2 (en) 2010-01-05 2014-11-18 Actelion Pharmaceuticals Ltd. Piperazines as antimalarial agents
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
CN105189485B (zh) 2013-03-15 2017-10-24 埃科特莱茵药品有限公司 作为抗疟剂的新型丙烯酰胺衍生物
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
US20220402916A1 (en) * 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2022140464A1 (en) * 2020-12-22 2022-06-30 Immunomolecular Therapeutics, Inc. Compounds and methods for treating autoimmune disorders by targeting hla-dq2
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1334705A (en) 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
US4258192A (en) 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
AU8868991A (en) 1990-11-15 1992-06-11 Pentapharm Ag Meta-substituted phenyl alanine derivatives
JPH07509731A (ja) 1993-02-10 1995-10-26 ペンタファルム アクチェンゲゼルシャフト トロンビン阻害剤としての置換されたフェニルアラニン誘導体のピペラジド
KR0173034B1 (ko) 1995-04-28 1999-03-30 성재갑 선택적 트롬빈 억제제
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
JP2003502314A (ja) * 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物

Similar Documents

Publication Publication Date Title
JP2004532886A5 (https=)
US10208002B2 (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US6995156B2 (en) Platelet adenosine diphosphate receptor antagonists
JP4327249B2 (ja) 抗ヘルペスウイルス性を有するフェニルチアゾール誘導体
JP2004513063A5 (https=)
JP2002533434A5 (https=)
US20050222222A1 (en) Pyrrolidine compounds
SK171399A3 (en) Piperazine derivatives and their use as anti-inflammatory agents
ES2282152T3 (es) Inhibidores de serina proteasa.
CA2507657A1 (en) 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
US20060276524A1 (en) 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
ES2436772T3 (es) Derivados de piperidina como inhibidores del virus del papiloma humano
US8466161B2 (en) Hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same
CN1324353A (zh) 新的脒衍生物,其制备方法,其作为药物的用途以及含有该化合物的药物组合物
JP2008524244A5 (https=)
WO2005021512A1 (en) Quinoxaline derivatives as neutrophil elastase inhibitors and their use
JP2005504093A5 (https=)
CN102596921B (zh) 新化合物
US20080119471A1 (en) Piperazine urea derivatives for the treatment of endometriosis
BR9815967A (pt) Processo para a preparação de um derivado de amino-5-cloro de 3(2h)-piridazinona-4-substituìdo
CN100451004C (zh) 嘧啶衍生物
ME01506B (me) MODULATORI INDOLAMIN 2,3-DIOKSIGENAZE l POSTUPCI UPOTREBE ISTIH
HK1117392B (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
HK1182381B (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same